Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile

European Journal of Pharmacology

Volumn 425, Issue 3, 2001, Pages 197-201

  Schmidt, Anne W ^a   Lebel, Lorraine ^a   Howard Jr , Harry R ^a   Zorn, Stevin ^a  

^a PFIZER INC   (United States)

Author keywords

Antipsychotic agent; Receptor binding, human; Ziprasidone

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; IMIPRAMINE; MUSCARINIC M1 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; ZIPRASIDONE;

ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG UPTAKE; EXTRAPYRAMIDAL SYMPTOM; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEROTONIN UPTAKE; TREATMENT OUTCOME; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; CLOZAPINE; DIBENZOTHIAZEPINES; DOPAMINE ANTAGONISTS; HALOPERIDOL; HUMANS; NEURONS; NOREPINEPHRINE; PIPERAZINES; PIRENZEPINE; RATS; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RISPERIDONE; SEROTONIN; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 0035902983     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01188-8     Document Type: Article

References (12)

1. Antipsychotic-induced weight gain: A comprehensive research synthesis
2. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain
3. The pharmacology of weight gain with antipsychotics
4. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
5. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
6. 35S]GTPγS binding study
7. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds
8. 1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex
9. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
10. 1A receptor activation
11. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
12. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy